Background/Aim: Physical component summary (PCS) and mental component summary (MCS) scores are associated with hospitalization and mortality in patients with end-stage renal disease. Most studies in these patients are cross-sectional in nature. This study aimed to assess the dynamics of health-related quality of life (HRQOL) over time, as well as determinants of changes in HRQOL. Also, the relation between changes in HRQOL with respect to both hospitalization and mortality was assessed. Methods: A cross-sectional analysis was performed in 77,848 hemodialysis (HD) patients whereas changes in HRQOL were assessed in 8,339 patients over a 1-year time period. HRQOL measurements were assessed with Kidney Disease Quality of Life-36 questionnaires. Also, relevant biomarkers (albumin, creatinine, hemoglobin, sodium) and equilibrated normalized protein catabolic rate (enPCR) were measured. Results: HRQOL were found to be decreased in HD patients. Nutritional indices like creatinine (r = 0.23; p < 0.0001) and serum albumin (r = 0.21; p < 0.0001) positively correlated with PCS scores. An increase in levels of albumin, creatinine, hemoglobin, enPCR and serum sodium over time are significantly (p < 0.0001) associated with positive changes in PCS scores. Changes in PCS scores were found to be predictive for hospitalization and mortality. The correlates of predictors for MCS scores were less strong compared to that of PCS scores. The strongest positive predictors of MCS scores were age (r = 0.08; p < 0.0001), albumin (r = 0.05; p < 0.0001) and sodium (r = 0.05; p < 0.0001). Conclusions: Nutritional factors are strongly associated with changes in HRQOL, especially with regard to PCS scores (change over time in HRQOL was an independent predictor of hospitalization and mortality). Increased scores of HRQOL over time are positively associated with survival.

Keywords:
Kidney disease quality of life-36, Retrospective cohort study
1.
Mazairac AH, de Wit GA, Penne EL, van der Weerd NC, de Jong B, Grooteman MP, et al: Changes in quality of life over time - Dutch haemodialysis patients and general population compared. Nephrol Dial Transplant 2011;26:1984-1989.
2.
Walters BA, Hays RD, Spritzer KL, Fridman M, Carter WB: Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis 2002;40:1185-1194.
3.
DeOreo PB: Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997;30:204-212.
4.
Mapes DL, Bragg-Gresham JL, Bommer J, Fukuhara S, McKevitt P, Wikström B, et al: Health-related quality of life in the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2004;44(5 suppl 2):54-60.
5.
Lowrie EG, Curtin RB, LePain N, Schatell D: Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 2003;41:1286-1292.
6.
Lopes AA, Bragg-Gresham JL, Satayathum S, McCullough K, Pifer T, Goodkin DA, et al: Health-related quality of life and associated outcomes among hemodialysis patients of different ethnicities in the United States: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2003;41:605-615.
7.
Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH: Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001;12:2797-2806.
8.
Spiegel BM, Melmed G, Robbins S, Esrailian E: Biomarkers and health-related quality of life in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol 2008;3:1759-1768.
9.
Avramovic M, Stefanovic V: Health-related quality of life in different stages of renal failure. Artif Organs 2012;36:581-589.
10.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
11.
Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
12.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
13.
Locatelli F, Del Vecchio L: Haemoglobin levels and health-related quality of life: a neglected hard end point. Nephrol Dial Transplant 2014;29:1272-1274.
14.
Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim R: Association between achievement of hemodialysis quality-of-care indicators and quality-of-life scores. Am J Kidney Dis 2009;54:1098-1107.
15.
Cruz MC, Andrade C, Urrutia M, Draibe S, Nogueira-Martins LA, Sesso Rde C: Quality of life in patients with chronic kidney disease. Clinics (Sao Paulo) 2011;66:991-995.
16.
Usvyat LA, Barth C, Bayh I, Etter M, von Gersdorff GD, Grassmann A, et al: Interdialytic weight gain, systolic blood pressure, serum albumin, and C-reactive protein levels change in chronic dialysis patients prior to death. Kidney Int 2013;84:149-157.
17.
Gabbay E, Meyer KB, Griffith JL, Richardson MM, Miskulin DC: Temporal trends in health-related quality of life among hemodialysis patients in the United States. Clin J Am Soc Nephrol 2010;5:261-267.
18.
Merkus MP, Jager KJ, Dekker FW, De Haan RJ, Boeschoten EW, Krediet RT: Quality of life over time in dialysis: the Netherlands cooperative study on the adequacy of dialysis. NECOSAD Study Group. Kidney Int 1999;56:720-728.
19.
Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, et al: Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. J Am Soc Nephrol 2004;15:743-753.
20.
Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB: Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994;3:329-338.
21.
Feeny D, Furlong W, Boyle M, Torrance GW: Multi-attribute health status classification systems. Health utilities index. Pharmacoeconomics 1995;7:490-502.
22.
Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim RM: A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients. Clin J Am Soc Nephrol 2010;5:252-260.
23.
Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA, The Health Institute, New England Medical Center, 1993.
24.
Ware JE, Kosinski M, Keller SD: SF-36 Physical and Mental Health Summary Scales: A User's Manual, ed 2. Boston, The Health Institute, New England Medical Center, 1994.
25.
Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, et al: Health-related quality of life among dialysis patients on three continents: the dialysis outcomes and practice patterns study. Kidney Int 2003;64:1903-1910.
26.
Mittal SK, Ahern L, Flaster E, Maesaka JK, Fishbane S: Self-assessed physical and mental function of haemodialysis patients. Nephrol Dial Transplant 2001;16:1387-1394.
27.
Allen KL, Miskulin D, Yan G, Dwyer JT, Frydrych A, Leung J, et al: Association of nutritional markers with physical and mental health status in prevalent hemodialysis patients from the HEMO study. J Ren Nutr 2002;12:160-169.
28.
Tanaka M, Yamazaki S, Hayashino Y, Fukuhara S, Akiba T, Saito A, et al: Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS. Nephrol Dial Transplant 2007;22:1658-1664.
29.
Kusek JW, Greene P, Wang SR, Beck G, West D, Jamerson K, et al: Cross-sectional study of health-related quality of life in African Americans with chronic renal insufficiency: the African American study of kidney disease and hypertension trial. Am J Kidney Dis 2002;39:513-524.
30.
Yeun JY, Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 1998;32(6 suppl 4):S118-S125.
31.
Odamaki M, Kato A, Takita T, Furuhashi M, Maruyama Y, Yonemura K, et al: Role of soluble receptors for tumor necrosis factor alpha in the development of hypoalbuminemia in hemodialysis patients. Am J Nephrol 2002;22:73-80.
32.
Kopple JD: McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance dialysis patients. Am J Clin Nutr 1997;65:1544-1557.
33.
Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001;60:333-340.
34.
Fouque D, Vennegoor M, ter Wee P, Wanner C, Basci A, Canaud B, et al: EBPG guideline on nutrition. Nephrol Dial Transplant 2007;22(suppl 2):ii45-ii87.
35.
Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, et al: Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008;3:348-354.
36.
van den Ham EC, Kooman JP, Schols AM, Nieman FH, Does JD, Franssen FM, et al: Similarities in skeletal muscle strength and exercise capacity between renal transplant and hemodialysis patients. Am J Transplant 2005;5:1957-1965.
37.
Brenner I: Exercise performance by hemodialysis patients: a review of the literature. Phys Sportsmed 2009;37:84-96.
38.
Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al: The Seattle heart failure model: prediction of survival in heart failure. Circulation 2006;113:1424-1433.
39.
Balling L, Schou M, Videbæk L, Hildebrandt P, Wiggers H, Gustafsson F: Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure. Eur J Heart Fail 2011;13:968-973.
40.
Flear CT, Singh CM: The sick cell concept and hyponatremia in congestive heart failure and liver disease. Lancet 1982;2:101-102.
41.
Flear CT, Gill GV, Burn J: Hyponatraemia: mechanisms and management. Lancet 1981;2:26-31.
42.
Okyay GU, Inal S, Oneç K, Er RE, Paşaoğlu O, Paşaoğlu H, et al: Neutrophil to lymphocyte ratio in evaluation of inflammation in patients with chronic kidney disease. Ren Fail 2013;35:29-36.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.